Company news
Hunan Fangsheng Pharmaceutical Co., Ltd. Class A (SSE:603998) news
Hunan Fangsheng Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Notice…
Press releases & updates
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Notice on Convening the 2nd Extraordinary General Meeting in 2026
September 29, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 6th Extraordinary Meeting of the 6th Board of Directors in 2026
September 29, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Progress of Transfer of Certain Equity Interests in a Controlled Subsidiary and Introduction of Strategic Investors
September 22, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Implementation of Dividend Distribution for the First Half of 2026
September 6, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Outline of the 2026 Semi-annual Performance and Cash Dividend Briefing
August 31, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Election of Employee Directors and Adjustment of the Remuneration and Appraisal Committee Members
August 28, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Resignation of Director and Deputy General Manager
August 26, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Progress of the Company's Acquisition of Pharmaceutical Production Technology
August 25, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Convening the 2026 Semi-annual Performance and Cash Dividend Briefing
August 20, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Proposed Selection of the Company's Products in the 12th Batch of the National Organized Centralized Volume-Based Drug Procurement
August 3, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Progress in Signing the Project Repurchase Agreement
July 28, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 4th Extraordinary Meeting of the 6th Board of Directors in 2026
July 20, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
July 15, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Inclusion of the Company's Main Products in the "National Essential Medicines List (2026 Edition)"
July 10, 2026
"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Change of "Drug Manufacturing License"
July 9, 2026
Announcement on Proposed Withdrawal from an M&A Fund and Related Party Transactions
June 29, 2026
Announcement on Progress in the Sale of Partial Equity in Investment Projects by the M&A Fund Participated in and Established by the Company
June 25, 2026
Announcement on Progress in Transferring Partial Equity of Holding Subsidiaries and Introducing Strategic Investors
June 22, 2026
Announcement on Resolutions of the 2nd Extraordinary Meeting of the 6th Board of Directors in 2026
June 8, 2026
Announcement on Progress in Drug Marketing Authorization Transfer
June 1, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 24, 2026
Announcement on Release of Pledge of Partial Shares of Controlling Shareholders
May 19, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 15, 2026
Announcement on Proposed Inclusion of Company Products in the Centralized Volume Procurement of National Chinese Patent Medicine Procurement Alliance
May 6, 2026
Announcement on Obtaining Summary Report of Phase III Clinical Trial for Pediatric Jingxing Anti-tussive Granules in Adults with Acute Tracheobronchitis (Syndrome of Wind-cold Transformation into Heat)
April 28, 2026
Announcement on Outline of the 2025 Annual and Q1 2026 Performance Briefing
April 27, 2026
2025 Annual Report
April 24, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
April 17, 2026
Announcement on Obtainment of the "Drug Registration Certificate" for Silapage Tablets
March 23, 2026
Announcement on Obtaining Drug Registration Certificate for Bisoprolol Amlodipine Tablets
March 4, 2026
Announcement on Continuation of Procurement for Products Selected in Centralized Procurement Agreements Upon Expiration of Agreement Period
March 2, 2026
Announcement on Soliciting Investor Opinions on Matters Related to 2025 Profit Distribution
February 27, 2026
Announcement on Pledge of Partial Shares of Controlling Shareholder
February 11, 2026
Announcement on Its Holding Subsidiary Obtaining the Drug Production License
February 5, 2026
Announcement on Obtainment of the "Drug Registration Certificate" for Loxoprofen Sodium Cataplasm
January 25, 2026
Announcement on Re-recognition of Wholly-owned Subsidiaries as High-tech Enterprises
January 22, 2026
Announcement on the Inspection Results of the Company's Transfer of Raw Material Production
January 11, 2026
Announcement on Special Dividend in 2025
January 5, 2026
Announcement on Outline of Investor Reception Day
December 21, 2025
Announcement on Subsidiary's Passing GMP Compliance Inspection for Drugs
December 16, 2025
Announcement on Resolutions of the 6th Extraordinary Meeting of the 6th Board of Directors in 2025
December 15, 2025
Announcement on Holding Investor Reception Day
December 12, 2025
Announcement on Inclusion of Innovative Traditional Chinese Medicine Yangxue Qufeng Zhitong Granules in the National Medical Insurance Catalog (2025)
December 8, 2025
Announcement on Obtainment of the "Drug Registration Certificate" for Indobufen Tablets
November 11, 2025
Announcement on Outline of the Q3 2025 Performance Briefing
October 24, 2025
Report for Q3 2025
October 23, 2025
Announcement on Change of ""Drug Manufacturing License"
October 21, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 16, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials by Subsidiary
October 15, 2025
Announcement on Drug Marketing Authorization Transfer
October 9, 2025